LL37: A Powerful Antimicrobial Factor in Human Health

LL-37 is the only cathelicidin antimicrobial peptide produced in the human body, and it plays a remarkably broad role in defending against infection, shaping immune responses, and even helping wounds heal. Found in white blood cells, skin cells, and the lining of the lungs and gut, this small protein fragment kills bacteria, fungi, and viruses through direct physical assault on their outer membranes. But calling it merely an “antimicrobial” undersells what it does. LL-37 also recruits immune cells to infection sites, tamps down dangerous inflammation, and disrupts the protective biofilms that make chronic infections so stubborn.

How LL-37 Is Made and Activated

Your body does not produce LL-37 in its finished, active form. Instead, cells first make a larger precursor protein called hCAP-18, which belongs to a family of proteins known as cathelicidins. The cathelicidin family is defined by a conserved structural region at one end and a variable antimicrobial region at the other. LL-37 is the antimicrobial end of hCAP-18, and it only becomes active after an enzyme physically snips it free from the rest of the molecule.¹

That cleavage happens outside the cell. When neutrophils, the most common type of white blood cell, release their stored granules in response to infection, an enzyme called proteinase 3 cuts hCAP-18 to liberate LL-37. Proteinase 3 is the sole enzyme responsible for this step among the serine proteases stored in neutrophil granules.² This arrangement makes sense: the peptide is kept safely inactive inside the cell and only released in its armed form right where it is needed.

Killing Microbes by Destroying Their Membranes

LL-37 carries a strong positive electrical charge, while bacterial membranes carry a negative one. That electrostatic attraction pulls the peptide straight toward microbial surfaces. Once enough LL-37 molecules accumulate on a bacterial membrane, they begin to dissolve it in a process researchers describe as a “carpet” mechanism: the peptides coat the membrane surface like a carpet, then act as detergents that tear it apart.³ Human cell membranes have a different composition and lack that strong negative charge, which is one reason LL-37 preferentially attacks invaders rather than the body’s own tissues.

Membrane disruption is not LL-37’s only trick. Against the drug-resistant fungus Candida auris, the peptide punches holes in the cell membrane while simultaneously driving up oxidative stress inside the fungal cell and arresting its ability to divide.⁴ That multi-pronged assault makes it much harder for a microbe to survive than if it only had to patch a single type of damage.

A Remarkably Broad Target Range

Most conventional antibiotics target either bacteria or fungi, and they tend to work against a limited set of species. LL-37 is different. A comprehensive review found that it is effective against more than 38 bacterial species, 16 fungi, and 16 viruses, deploying mechanisms that range from direct membrane rupture to interference with viral entry and replication.⁵ This kind of breadth is unusual for a single molecule and helps explain why LL-37 has attracted so much interest as a potential therapeutic agent.

The antiviral activity is particularly striking because most antimicrobial peptides are studied primarily for their antibacterial effects. LL-37 can disrupt viral envelopes, the lipid coats that many viruses rely on to enter host cells, and can interfere with later stages of viral replication. That dual-threat capability against both bacterial and viral pathogens makes LL-37 a versatile first responder during the early hours of an infection, before the adaptive immune system has had time to mount a targeted response.

Breaking Up Biofilms

Biofilms are communities of bacteria encased in a slimy, protective matrix that makes them dramatically more resistant to antibiotics. Chronic wound infections, urinary-tract infections on catheters, and lung infections in people with cystic fibrosis all commonly involve biofilms. LL-37 can prevent biofilm formation at concentrations far below what is needed to outright kill bacteria. In laboratory experiments, it blocked biofilm development at about 0.5 micrograms per milliliter, a dose roughly 128 times lower than the concentration required to kill bacteria in free-floating form. It could also disrupt biofilms that had already established themselves.⁶

This is one of the findings researchers get most excited about, because biofilm-associated infections are among the hardest to treat clinically. The fact that LL-37 works against biofilms at such low concentrations suggests it could complement conventional antibiotics that struggle to penetrate the biofilm matrix.

More Than a Killer: How LL-37 Shapes Immune Responses

LL-37’s role in immunity goes well beyond directly destroying pathogens. It acts as a signaling molecule that draws other immune cells to an infection site. The peptide is chemotactic for neutrophils, monocytes, and T cells, meaning it pulls these defenders toward the area where it has been released. It does this by binding to a receptor called FPRL1 on the surface of those immune cells.⁷ By recruiting both innate and adaptive immune cells, LL-37 acts as a bridge between the body’s fast, nonspecific defenses and its slower, highly targeted ones.

At the same time, LL-37 helps prevent the immune system from overreacting. In severe bacterial infections, fragments of bacterial cell walls called lipopolysaccharide (LPS) can trigger a runaway inflammatory response that damages the host’s own tissues, sometimes fatally. LL-37 binds directly to LPS and neutralizes it, blocking the signaling cascade that would otherwise cause immune cells to release a flood of inflammatory molecules.⁸ In animal models of sepsis caused by gram-negative bacteria, LL-37 treatment reduced both endotoxin and inflammatory-marker levels in the blood, performing comparably to polymyxin B, a drug specifically used to neutralize endotoxin.⁹

LL-37 can also block a particularly destructive form of inflammatory cell death called pyroptosis. In macrophages exposed to bacterial toxins, LL-37 suppressed the activation of the molecular machinery that triggers pyroptosis, doing so by both neutralizing LPS and blocking the signaling that another danger signal, ATP, uses to push the cell toward self-destruction.¹⁰

The Vitamin D Connection

One of the most compelling discoveries about LL-37 is that its production is directly regulated by vitamin D. When active vitamin D binds to its receptor inside immune cells and skin cells, it switches on the gene that codes for hCAP-18, the precursor of LL-37.¹¹ This link between vitamin D and antimicrobial peptide production has helped explain a long-standing puzzle: why vitamin D deficiency is associated with increased vulnerability to infections. If your vitamin D levels are low, your body may produce less LL-37 and mount a weaker innate immune response.

This regulation appears to be a human and primate-specific adaptation. Mice and other non-primate mammals have their own cathelicidin peptides, but those genes are not controlled by vitamin D in the same way.¹² That evolutionary detail matters for research: mouse studies of cathelicidin function are useful for understanding the peptide’s direct antimicrobial effects, but they don’t model the vitamin D regulatory axis the way human biology works.

Wound Healing and Tissue Repair

When skin is injured, cathelicidin expression ramps up at the wound edge. This increase in LL-37 happens alongside the upregulation of other components of innate immunity, including molecules that help cells recognize bacterial invaders and mount a local defense.¹³ So the wound essentially arms itself against infection as part of the normal healing process, and vitamin D is part of the trigger.

Beyond defending against infection at the wound site, LL-37 directly promotes tissue repair. In studies of corneal epithelial cells, LL-37 activated growth-factor signaling pathways and accelerated the closure of scratch wounds. It even partially rescued wound healing that had been impaired by high glucose levels, a finding with relevance for people with diabetes, who are notoriously prone to slow-healing wounds.¹⁴

Skin Diseases and the LL-37 Imbalance

The contrast between psoriasis and atopic dermatitis (eczema) illustrates just how much LL-37 levels matter for skin health. Psoriatic skin is packed with LL-37, and people with psoriasis rarely develop bacterial skin infections. Eczema tells the opposite story: lesional skin from people with atopic dermatitis contains significantly less LL-37 than psoriatic skin, and these patients are frequently plagued by infections with Staphylococcus aureus and other bacteria.¹⁵ When researchers tested combinations of LL-37 and another antimicrobial peptide called HBD-2, the two worked synergistically to kill S. aureus, suggesting that the deficit in atopic dermatitis is not just about one peptide but about a weakened antimicrobial cocktail overall.

More recent work has confirmed that LL-37 is unique among antimicrobial peptides in being specifically impaired in atopic dermatitis. While most other antimicrobial peptides were either unchanged or elevated in eczema lesions, LL-37 was the only one that decreased compared to healthy skin. It was also reduced in non-lesional atopic skin, suggesting the deficiency is a systemic feature of the disease rather than a consequence of active inflammation.¹⁶

Psoriasis, though, shows that more LL-37 is not always better. In psoriatic skin, LL-37 can form complexes with fragments of RNA released from damaged cells, and these complexes amplify inflammation. Neutrophils exposed to RNA-LL-37 complexes released substantially more of the inflammatory signal IL-8 than neutrophils exposed to RNA alone, and LL-37 boosted the uptake of that RNA into immune cells fourfold.¹⁷ This creates a feedback loop: inflammation produces cell damage, damaged cells release RNA, LL-37 ferries that RNA into immune cells, and those immune cells fire off more inflammatory signals. It is a textbook case of a beneficial molecule causing harm when it accumulates in the wrong context.

LL-37 in the Lungs and Gut

LL-37 shows up wherever the body meets the outside world. In the lungs, infection with Mycobacterium tuberculosis triggers alveolar macrophages, monocytes, neutrophils, and epithelial cells to produce LL-37. Alveolar macrophages, the resident immune cells of the lung’s air sacs, were the most efficient producers. Interestingly, the peptide was not detected in established tuberculosis granulomas, suggesting LL-37 acts mainly during the earliest phase of infection, before the immune system walls off the bacteria.¹⁸

In the gut, LL-37 appears to do double duty. In a mouse model of infection with E. coli O157:H7, a dangerous strain that causes bloody diarrhea and kidney damage, treatment with LL-37 reduced intestinal inflammation, decreased immune-cell infiltration into the gut wall, and increased the production of tight-junction proteins that hold the intestinal barrier together. It also helped restore the balance of gut bacteria that the infection had disrupted.¹⁹ Protecting barrier integrity is a big deal: a leaky gut wall lets bacteria and toxins escape into the bloodstream and can set off systemic inflammation.

LL-37 in the Mouth

The fluid that seeps from your gums, called gingival crevicular fluid, is rich in LL-37. Researchers have found that its concentration rises in people with chronic periodontitis, scaling in proportion to the burden of key periodontal pathogens including Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola.²⁰ The peptide likely serves as a first line of defense at the gum line, but the fact that its levels climb alongside bacterial load in disease suggests it is not always enough to tip the balance in the host’s favor. The microbial community in a deep periodontal pocket is protected by biofilm and sheer numbers, and LL-37 production may be a response to infection rather than a successful defense.

The Complicated Relationship With Cancer

Perhaps the most surprising chapter in the LL-37 story is its role in cancer, where it can either fuel tumor growth or suppress it depending on the tissue involved. Overexpression of LL-37 has been linked to the development or progression of ovarian, lung, and breast cancers, while in gastric and colon cancers, it appears to inhibit tumor growth.²¹ The mechanisms behind this split personality are tissue-specific and depend on which receptors are present on the cancer cells. LL-37 can act as a signaling molecule that binds to various cell-surface receptors, and different cancer types express different receptor profiles, so the downstream effect of LL-37 binding varies dramatically.²²

This dual nature complicates any therapeutic strategy that aims to boost LL-37 levels systemically. A treatment that raises LL-37 to fight infection might, in theory, create a more favorable environment for certain tumors. The cancer research is still at an early stage, and no clinical guidelines have changed because of it, but it is a factor that researchers working on LL-37-based drugs must account for.

How Bacteria Fight Back

Bacteria have not been passive targets. Over evolutionary time, many pathogens have developed strategies to resist antimicrobial peptides, including LL-37. Common evasion tactics include modifying the electrical charge on their outer surfaces to repel the positively charged peptide, pumping it back out using efflux systems, altering membrane fluidity to resist disruption, chopping it up with proteases, and trapping it with surface proteins or polysaccharides before it can reach the membrane.²³

Staphylococcus aureus, one of the most clinically important human pathogens, uses a network of resistance genes to fend off LL-37. Among these, a gene called mprF modifies the bacterial membrane by adding positively charged molecules to it, reducing the electrostatic attraction that normally draws LL-37 in. When researchers disabled mprF, the bacteria became substantially more permeable to LL-37-derived peptides.²⁴ Understanding these resistance mechanisms is helping drug designers create modified versions of LL-37 that are harder for bacteria to deflect.

From Peptide to Drug

The therapeutic potential of LL-37 is real, but so are the obstacles. The peptide is expensive to manufacture, loses much of its activity in the salt-rich environment of bodily fluids, breaks down quickly when exposed to the body’s own protein-digesting enzymes, and can damage human cells at the concentrations needed to kill bacteria effectively.²⁵ These are not trivial problems, and they have so far prevented LL-37 itself from becoming a mainstream drug.

Researchers are attacking these limitations from several angles. One approach is to design shorter peptides derived from LL-37 that retain the killing power but are cheaper to make and less toxic to host cells. Two such engineered peptides, OP-145 and SAAP-148, are each only 24 amino acids long (compared to LL-37’s 37) and show killing activity against both gram-positive and gram-negative bacteria at similar concentrations.²⁶ Another strategy involves packaging LL-37 in nanoparticle delivery systems that protect the peptide from degradation and release it slowly at the wound site, addressing both the stability and toxicity problems at once.²⁷

A third and arguably more accessible strategy is to combine LL-37 with existing antibiotics. Against multidrug-resistant E. coli strains, LL-37 and the antibiotic colistin showed synergistic effects, meaning the combination worked better than either agent alone, even against bacteria that had developed resistance to colistin by itself.²⁸ Combination approaches could lower the dose of both agents needed, reducing cost and side effects while making it harder for bacteria to develop resistance to either one.

Why Mice Are an Imperfect Stand-In

Much of what we know about cathelicidin function comes from studies in mice, which produce their own version of the peptide called CRAMP. The mouse CRAMP gene shares structural similarities and several transcription-factor binding sites with the human LL-37 gene, making mice a reasonable model for studying the peptide’s direct antimicrobial and wound-healing effects.²⁹ But as noted earlier, the vitamin D regulation of cathelicidin expression that is so important in humans does not exist in mice. Any mouse experiment designed to test whether vitamin D supplementation boosts antimicrobial peptide defenses is, at best, testing a simplified version of the human system. This gap matters for interpreting clinical claims about vitamin D and immune function, because a key piece of the mechanism simply is not present in the most common laboratory animal.